News
Spiraling in on animal development
In recent years scientists have determined the genome sequence of many animals, but many gaps still exist in the animal evolutionary tree. Headway was recently made, however, and three branches representing spiralian animals have now been sequenced. HudsonAlpha faculty investigator Jane Grimwood, Ph.D., contributed to the multi-institute study that spirals in on animal evolution. The study is published in the journal Nature.
BioTrain Poster Day featured in The Huntsville Times
Mushroom history could advance energy future
HUNTSVILLE, Ala.-- Fossil evidence suggests that coal deposits in the earth sharply decreased around the end of the Carboniferous period. Using genome sequence of fungi living now, Jeremy Schmutz from the HudsonAlpha Institute for Biotechnology and colleagues around the world say mushrooms may hold the clues to this decrease while also providing insight to spur technical progress for cellulosic biofuels production.
HUNTSVILLE, Ala -- Serina Therapeutics, Inc., announced today that the company has entered into a definitive exclusive license agreement with The Scripps Research Institute for “click chemistry” – a facile method of attaching molecules together in a precise and quantitative manner. The nature of the agreement and the financial terms were not disclosed.
Huntsville, AL (PRWEB) January 29 -- TransOMIC technologies announced today that it has partnered with Clontech (a Takara Bio company) to launch the MGC premier™ Tagged ORF collections for gene and protein analysis. Over 40,000 human, mouse and rat genes are represented in these new genome-scale ORF collections, making transOMIC technologies the largest provider of gene content for protein expression.
No one has done more to push Alabama’s image as a leader in biotechnology than Huntsville’s Jim Hudson, one of the founders of the HudsonAlpha Institute for Biotechnology.
HUNTSVILLE, Ala. - CFD Research Corporation, CFDRC, has been awarded a $1.3M grant from the National Institutes of Health to further develop their novel in vitro Blood-Brain Barrier model. Building upon CFDRC’s patented and commercially available SynVivo platform, SynVivo-BBB is a cell-based microchip which allows co-culture of endothelial cells under physiological flow with neuronal and glial cells mimicking the in vivo environment.